|This Slide: #46 of 83|
Slide #46. Asterias Biotherapeutics, Inc — Geron's Embryonic Stem Cell Assets
Asterias Biotherapeutics, Inc (AMEX:BTX)
Geron's Embryonic Stem Cell Assets
Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT:BTX) jointly announced today the closing of the transactions under the Asset Contribution Agreement (the "Agreement") with Geron Corporation, previously announced on January 7, 2013, pursuant to which Asterias Biotherapeutics acquired Geron's human embryonic stem (hES) cell assets, as well as rights to use certain human embryonic stem cell lines, minority stakes in two of BioTime's subsidiaries and stock from BioTime.
Brooklyn ImmunoTherapeutics provides interactive entertainment and technology to its partners in a range of verticals - from bars and restaurants to casinos and senior living centers. Co.'s principal product and service is its interactive entertainment system that provides trivia, card, sports and arcade games through an extended network platform. Generally, as part of the subscription to its platform, Co. provides the equipment for the platform to network subscribers, though Co. has also leased such equipment to certain network subscribers. Co. licenses its content to customers to be installed on equipment they obtain from other parties.
Open the BTX Page at The Online Investor »
Strong Buy (3.67 out of 4)
(ranked higher than approx. 94% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite